Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Abstract Objectives In Thailand, axillary lymph node dissection (ALND) is the dominant form of treatment for breast cancer, even though the treatment often leaves patients with some degree of arm morbidity. Sentinel lymph node biopsy (SNB) is widely accepted globally as a preferable alternative pr

Hialy Gutierrez, MPH,1,2 Ashwini Shewade, MS, MSc,1 Minghan Dai, MPH,1 Pedro Mendoza-Arana, MD, MSc,3 Octavio Go´mez-Dante´s, MD, MPH,4 Nishant Jain, PhD,5 Irma Khonelidze, MPA,6 Juliet Nabyonga-Orem, MD, MSc,7 Karima Saleh, PhD,8 Yot Teerawattananon, MD, PhD,9 Sania Nishtar, SI, PhD,10 and John Hor

Objective: To analyze the cost-utility of two common clinical practices for stage IB cervical cancer patients from provider and societal viewpoints. Methods: A decision tree model was conducted to examine value for expenditure between the following: (1) radical hysterectomy with pelvic lymph node

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Yot Teerawattananon, Alia Luz* , Songyot Pilasant, Suteenoot Tangsathitkulchai, Sarocha Chootipongchaivat, Nattha Tritasavit, Inthira Yamabhai and Sripen Tantivess Abstract Background: It is very challenging for resource-limited settings to introduce universal health coverage (UHC), particular

Sripen Tantivess & Viroj Tangcharoensathien Abstract Thailand achieves universal health coverage through the introduction of 3 benefit schemes: the Civil Servant Medical Benefit Scheme (CSMBS), Social Security Scheme, and Universal Coverage Scheme. The primary benefit package of these sche

Objective: Implementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis